行情

AIMT

AIMT

Aimmune治疗
NASDAQ

实时行情|Nasdaq Last Sale

22.38
-0.84
-3.62%
已收盘, 19:59 09/17 EDT
开盘
22.95
昨收
23.22
最高
23.21
最低
22.02
成交量
173.23万
成交额
--
52周最高
36.12
52周最低
16.95
市值
14.03亿
市盈率(TTM)
-6.0097
分时
5日
1月
3月
1年
5年

分析师评级

10位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

AIMT 新闻

  • 日本社交巨头Line推出加密交易平台Bitmax
  • TechWeb.37分钟前
  • WeWork拟今年完成IPO:估值缩水八成,创始人表悔意
  • 澎湃新闻.43分钟前
  • 财经天下:IMF新掌门将面临哪些挑战?
  • 中国新闻网.47分钟前
  • 13家大型投行前瞻:美联储料降息25个基点 微调声明
  • 汇通网.52分钟前

更多

所属板块

生物技术和医学研究
+0.26%
制药与医学研究
+0.57%

热门股票

名称
价格
涨跌幅

AIMT 简况

Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company's therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services. The Company's lead CODIT product candidate, AR101, is an investigational biologic for the treatment of patients with peanut allergy. The Company has initiated Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE), its Phase III registration trial of AR101. The Company is in the process of evaluating additional delivery forms for AR101 for the maintenance phase.
展开

Webull提供Aimmune Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。